Analysis of PD-1+ tumor-infiltrating T cells according to cancer antigen hierarchy

• Project/Area Number: 20H03694
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Review Section: Basic Section 53030:Respiratory medicine-related
• Research Institution: Okayama University (2021-2022); Chiba Cancer Center (Research Institute) (2020)
• Principal Investigator: Togashi Yosuke 岡山大学, 医歯薬学域, 教授 (80758326)
• Co-Investigator(Kenkyū-buntansha): 盛永 敬郎 千葉県がんセンター(研究所), がん治療開発グループ 細胞治療開発研究部, 研究員 (30757000)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Project Status: Completed (Fiscal Year 2022)
• Budget Amount: ¥17,810,000 (Direct Cost: ¥13,700,000、Indirect Cost: ¥4,110,000); Fiscal Year 2022: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000); Fiscal Year 2021: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000); Fiscal Year 2020: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
• Keywords: 腫瘍免疫 / ネオ抗原 / PD-1 / 制御性T細胞 / がん抗原 / 肺癌

Outline of Research at the Start

抗PD-1/PD-L1抗体はT細胞を活性化しがんに対して効果を発揮している。特に体細胞変異由来のネオ抗原は強い免疫応答を起こすことができるため、それらを認識しているエフェクターT細胞が重要である。申請者は肺癌の臨床検体から腫瘍浸潤T細胞のPD-1発現のバランスが抗PD-1/PD-L1抗体の効果・耐性に関与することを明らかにした。本研究はさらに発展させ、ネオ抗原や共通抗原といった認識するがん抗原の階層性に基づくT細胞のPD-1発現といった表現型や機能の違いを明らかにし、より効果の高い治療や正確なバイオマーカー、個別化細胞療法の基盤データを得ることを目指す。

Outline of Final Research Achievements

Cancer is believed to exist as "cancer" by escaping from antitumor immunity using suppressive molecules and/or suppressive cells such as PD-1/PD-L1 and regulatory T cells (Treg). Since anti-PD-1/PD-L1 antibodies exert their effects by activating the effector capacity of T cells, responders to anti-PD-1/PD-L1 antibodies had high frequency of PD-1+ effector T cells in the tumor microenvironment. Such T cells recognized neoantigens. In contrast, PD-1+ Tregs highly infiltrated in resistant patients. We have shown that suppressiive functuons of PD-1+ Tregs are activated by PD-1 blockade. Furthermore, a specific metabolic environment was involved in PD-1 expression in Tregs.

Academic Significance and Societal Importance of the Research Achievements

腫瘍浸潤PD-1陽性エフェクターT細胞ががん免疫療法の効果に関与し、同時にPD-1陽性Tregが耐性に関与することを明らかにでき、効果予測を正確に行えるようになった。また、新たにPD-1陽性Tregが標的となり得て、そこに代謝環境が関与するため、代謝による制御も新たなコンセプトの治療になり得ると考えられた。これらはがん免疫療法のさらなる治療成績の向上に繋がると考えている。

Research Products

• [Journal Article] High Expression of MHC Class I Overcomes Cancer Immunotherapy Resistance Due to IFNγ Signaling Pathway Defects (2023)
  • Author(s): Kawase K、Kawashima S、Nagasaki J、Inozume T、Tanji E、Kawazu M、Hanazawa T、Togashi Y
  • Journal Title: Cancer Immunology Research Volume: In press Issue: 7 Pages: 895-908
  • DOI: 10.1158/2326-6066.cir-22-0815
  • Peer Reviewed
• [Journal Article] Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity (2023)
  • Author(s): Watanabe T、Ishino T、Ueda Y、Nagasaki J、Sadahira T、Dansako H、Araki M、Togashi Y
  • Journal Title: Cancer Science Volume: In press Issue: 5 Pages: 1859-1870
  • DOI: 10.1111/cas.15756
  • Peer Reviewed / Open Access
• [Journal Article] Somatic mutations can induce a noninflamed tumour microenvironment via their original gene functions, despite deriving neoantigens (2023)
  • Author(s): Ishino Takamasa、Kawashima Shusuke、Tanji Etsuko、Ueno Toshihide、Ueda Youki、Ogasawara Sadahisa、Sato Kazuhito、Mano Hiroyuki、Ishihara Soichiro、Kato Naoya、Kawazu Masahito、Togashi Yosuke
  • Journal Title: British Journal of Cancer Volume: 128 Issue: 6 Pages: 1166-1175
  • DOI: 10.1038/s41416-023-02165-6
  • Peer Reviewed / Open Access
• [Journal Article] Tumor-promoting function and regulatory landscape of PD-L2 in B-cell lymphoma (2022)
  • Author(s): Shingaki S、Koya J、Yuasa M、Saito Y、Tabata M、McClure MB、Ogawa S、Katayama K、Togashi Y、Imoto S、Kogure Y、Kataoka K
  • Journal Title: Leukemia Volume: 37 Issue: 2 Pages: 492-496
  • DOI: 10.1038/s41375-022-01772-1
  • Peer Reviewed
• [Journal Article] Resistance to immune checkpoint inhibitors and the tumor microenvironment (2022)
  • Author(s): Kawashima S、Togashi Y
  • Journal Title: Experimental Dermatology Volume: 32 Issue: 3 Pages: 240-249
  • DOI: 10.1111/exd.14716
  • Peer Reviewed
• [Journal Article] Mechanisms of resistance to immune checkpoint inhibitors (2022)
  • Author(s): Nagasaki J、Ishino T、Togashi Y
  • Journal Title: Cancer Science Volume: 113 Issue: 10 Pages: 3303-3312
  • DOI: 10.1111/cas.15497
  • Peer Reviewed / Open Access
• [Journal Article] A variety of ‘exhausted’ T cells in the tumor microenvironment (2022)
  • Author(s): Nagasaki J、Togashi Y
  • Journal Title: International Immunology Volume: 34 Issue: 11 Pages: 563-570
  • DOI: 10.1093/intimm/dxac013
  • Peer Reviewed / Open Access
• [Journal Article] Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration (2022)
  • Author(s): T. Morinaga, T. Inozume, Y. Togashi et al.
  • Journal Title: Cancer Research Communications Volume: 2 Issue: 7 Pages: 739-753
  • DOI: 10.1158/2767-9764.crc-22-0050
  • Peer Reviewed / Open Access
• [Journal Article] HLA Class I Analysis Provides Insight Into the Genetic and Epigenetic Background of Immune Evasion in Colorectal Cancer With High Microsatellite Instability (2022)
  • Author(s): Kawazu M, Ueno T, Saeki K, Sax N, Togashi Y, Kanaseki T, Chida K, Kishigami F, Sato K, Kojima S, Tanegashima T, Matsubara D, Tane K, Tanaka Y, Iinuma H, Hashiguchi Y, Hazama S, Khor SS, Tokunaga K, Tsuboi M, Niki T, Eto M, Shitara K, Torigoe T, Ishihara S, Aburatani H, Haeno H, Nishikawa H, Mano H
  • Journal Title: Gastroenterology Volume: 162 Issue: 3 Pages: 799-812
  • DOI: 10.1053/j.gastro.2021.10.010
  • Peer Reviewed / Open Access
• [Journal Article] Programmed Death-Ligand 1-Rich Premetastatic Niche in Adjuvant Chemotherapy (2022)
  • Author(s): Yamamoto Hiromasa、Togashi Yosuke
  • Journal Title: Journal of Thoracic Oncology Volume: 17 Issue: 1 Pages: 10-12
  • DOI: 10.1016/j.jtho.2021.10.019
  • Peer Reviewed
• [Journal Article] Preoperative Chemoradiotherapy Plus Nivolumab Before Surgery in Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer Patients (2022)
  • Author(s): Bando H, Tsukada Y, Inamori K, Togashi Y, Koyama S, Kotani D, Fukuoka S, Yuki S, Komatsu Y, Homma S, Taketomi A, Uemura M, Kato T, Fukui M, Wakabayashi M, Nakamura N, Kojima M, Kawachi H, Kirsch R, Yoshida T, Suzuki Y, Sato A, Nishikawa H, Ito M, Yoshino T
  • Journal Title: Clinical Cancer Research Volume: 28 Issue: 6 Pages: 1136-1146
  • DOI: 10.1158/1078-0432.ccr-21-3213
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments (2022)
  • Author(s): Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin YT, Togashi Y, Kamada T, Irie T, Okumura G, Kono H, Ito D, Fujii R, Watanabe S, Sai A, Aokage K, Suzuki J, Ishii G, Kuwata T, Sakamoto N, Kawazu M, Ueno T, Mori T, Yamazaki N, Tsuboi M, Yatabe Y, Kinoshita T, Doi T, Shitara K, Mano H, Nishikawa H
  • Journal Title: Cancer Cell Volume: 40 Issue: 2 Pages: 201-218
  • DOI: 10.1016/j.ccell.2022.01.001
  • Peer Reviewed / Open Access
• [Journal Article] PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes (2022)
  • Author(s): Nagasaki Joji、Inozume Takashi、Yosuke Togashi et al.
  • Journal Title: Cell Reports Volume: 38 Issue: 5 Pages: 110331-110331
  • DOI: 10.1016/j.celrep.2022.110331
  • NAID: 120007192058
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer (2021)
  • Author(s): Inamori Koji、Togashi Yosuke、Fukuoka Shota、Akagi Kiwamu、Ogasawara Kouetsu、Irie Takuma、Motooka Daisuke、Kobayashi Yoichi、Sugiyama Daisuke、Kojima Motohiro、Shiiya Norihiko、Nakamura Shota、Maruyama Shoichi、Suzuki Yutaka、Ito Masaaki、Nishikawa Hiroyoshi
  • Journal Title: JCI Insight Volume: 8 Issue: 9 Pages: 137365-137365
  • DOI: 10.1172/jci.insight.137365
  • Peer Reviewed / Open Access
• [Journal Article] Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1 (2021)
  • Author(s): Koya J, Saito Y, Kameda T, Kogure Y, Yuasa M, Nagasaki J, McClure MB, Shingaki S, Tabata M, Tahira Y, Akizuki K, Kamiunten A, Sekine M, Shide K, Kubuki Y, Hidaka T, Kitanaka A, Nakano N, Utsunomiya A, Togashi Y, Ogawa S, Shimoda K, Kataoka K
  • Journal Title: Blood Cancer Discovery Volume: 2 Issue: 5 Pages: 450-467
  • DOI: 10.1158/2643-3230.bcd-21-0044
  • NAID: 120007145001
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment (2021)
  • Author(s): Kawashima S, Inozume T, Kawazu M, Ueno T, Nagasaki J, Tanji E, Honobe A, Ohnuma T, Kawamura T, Umeda Y, Nakamura Y, Kawasaki T, Kiniwa Y, Yamasaki O, Fukushima S, Ikehara Y, Mano H, Suzuki Y, Nishikawa H, Matsue H, Togashi Y.
  • Journal Title: Journal for ImmunoTherapy of Cancer Volume: 9 Issue: 11 Pages: e003134-e003134
  • DOI: 10.1136/jitc-2021-003134
  • NAID: 120007175403
  • Peer Reviewed / Open Access
• [Journal Article] Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape (2021)
  • Author(s): Takeuchi Y, Tanegashima T, Sato E, Irie T, Sai A, Itahashi K, Kumagai S, Tada Y, Togashi Y, Koyama S, Akbay EA, Karasaki T, Kataoka K, Funaki S, Shintani Y, Nagatomo I, Kida H, Ishii G, Miyoshi T, Aokage K, Kakimi K, Ogawa S, Okumura M, Eto M, Kumanogoh A, Tsuboi M, Nishikawa H
  • Journal Title: Science Immunology Volume: 6 Issue: 65
  • DOI: 10.1126/sciimmunol.abc6424
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Transcript-targeted analysis reveals isoform alterations and double-hop fusions in breast cancer (2021)
  • Author(s): Namba Shinichi、Ueno Toshihide、Kojima Shinya、Kobayashi Kenya、Kawase Katsushige、Tanaka Yosuke、Inoue Satoshi、Kishigami Fumishi、Kawashima Shusuke、Maeda Noriko、Ogawa Tomoko、Hazama Shoichi、Togashi Yosuke、Ando Mizuo、Shiraishi Yuichi、Mano Hiroyuki、Kawazu Masahito
  • Journal Title: Communications Biology Volume: 4 Issue: 1 Pages: 1320-1320
  • DOI: 10.1038/s42003-021-02833-4
  • Peer Reviewed / Open Access
• [Journal Article] Aging, cancer, and antitumor immunity (2021)
  • Author(s): Ikeda Hideki、Togashi Yosuke
  • Journal Title: International Journal of Clinical Oncology Volume: Epub Issue: 2 Pages: 316-322
  • DOI: 10.1007/s10147-021-01913-z
  • Peer Reviewed
• [Journal Article] HSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR-TKIs (2021)
  • Author(s): Watanabe S, Goto Y, Yasuda H, Kohno T, Motoi N, Ohe Y, Nishikawa H, Kobayashi SS, Kuwano K, Togashi Y.
  • Journal Title: Thoracic Cancer Volume: 12 Issue: 5 Pages: 631-42
  • DOI: 10.1111/1759-7714.13839
  • Peer Reviewed / Open Access
• [Journal Article] Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens (2021)
  • Author(s): Kashima Yukie、Togashi Yosuke、Fukuoka Shota、et al.
  • Journal Title: Scientific Reports Volume: 11 Issue: 1 Pages: 341-341
  • DOI: 10.1038/s41598-020-79385-w
  • Peer Reviewed / Open Access
• [Journal Article] Vaginal Transmission of Cancer from Mothers with Cervical Cancer to Infants (2021)
  • Author(s): Arakawa A, Ichikawa H, Kubo T, Motoi N, Kumamoto T, Nakajima M, Yonemori K, Noguchi E, Sunami K, Shiraishi K, Kakishima H, Yoshida H, Hishiki T, Kawakubo N, Kuroda T, Kiyokawa T, Yamada K, Yanaihara N, et al, and Kohno T, Ogawa C.
  • Journal Title: New England Journal of Medicine Volume: 384 Issue: 1 Pages: 42-50
  • DOI: 10.1056/nejmoa2030391
  • Peer Reviewed / Open Access
• [Journal Article] Heterogeneity in congenital melanocytic nevi contributes to multicentric melanomagenesis (2020)
  • Author(s): Honobe Akiko、Sakai Kazuko、Togashi Yosuke、Ohnuma Takehiro、Kawamura Tatsuyoshi、Nishio Kazuto、Inozume Takashi
  • Journal Title: Journal of Dermatological Science Volume: 100 Issue: 3 Pages: 217-219
  • DOI: 10.1016/j.jdermsci.2020.09.004
  • Peer Reviewed
• [Journal Article] The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies (2020)
  • Author(s): Kumagai S,Togashi Y,Kamada T,Sugiyama E,Nishinakamura H,Takeuchi Y,Vitaly K,Itahashi K,Maeda Y,Matsui S,Shibahara T,Yamashita Y,Irie T,Tsuge A,Fukuoka S,Kawazoe A,Udagawa H,Kirita K,Aokage K,Ishii G,Kuwata T,Nakama K,Kawazu M,Ueno T,Yamazaki N,Goto K,Tsuboi M,Mano H,Doi T,Shitara K,Nishikawa H
  • Journal Title: Nature Immunology Volume: 21 Issue: 11 Pages: 1346-1358
  • DOI: 10.1038/s41590-020-0769-3
  • Peer Reviewed / Open Access
• [Journal Article] Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial (2020)
  • Author(s): Hayashi, H. Takiguchi, Y. Minami, H. Akiyoshi, K. Segawa, Y. Ueda, H. Iwamoto, Y. Kondoh, C. Matsumoto, K. Takahashi, S. Yasui, H. Sawa, T. Onozawa, Y. Chiba, Y. Togashi, Y. Fujita, Y. Sakai, K. Tomida, S. Nishio, K. Nakagawa, K.
  • Journal Title: JAMA Oncol Volume: 6 Issue: 12 Pages: 1931-1938
  • DOI: 10.1001/jamaoncol.2020.4643
  • Peer Reviewed / Open Access
• [Journal Article] The critical role of CD4+ T cells in PD-1 blockade against MHC-II?expressing tumors such as classic Hodgkin lymphoma (2020)
  • Author(s): Nagasaki Joji、Togashi Yosuke、Sugawara Takeaki、Itami Makiko、Yamauchi Nobuhiko、Yuda Junichiro、Sugano Masato、Ohara Yuuki、Minami Yosuke、Nakamae Hirohisa、Hino Masayuki、Takeuchi Masahiro、Nishikawa Hiroyoshi
  • Journal Title: Blood Advances Volume: 4 Issue: 17 Pages: 4069-4082
  • DOI: 10.1182/bloodadvances.2020002098
  • Peer Reviewed / Open Access
• [Journal Article] Enhanced Tumor Response to Radiotherapy After PD-1 Blockade in Metastatic Gastric Cancer (2020)
  • Author(s): Sasaki A, Nakamura Y, Togashi Y, Kuno H, Hojo H, Kageyama S, Nakamura N, Takashima K, Kadota T, Yoda Y, Mishima S, Sawada K, Kotani D, Kawazoe A, Kuboki Y, Taniguchi H, Kojima T, Doi T, Yoshino T, Yano T, Kobayashi T, Akimoto T, Nishikawa H, Shitara K.
  • Journal Title: Gastric Cancer Volume: - Issue: 5 Pages: 893-903
  • DOI: 10.1007/s10120-020-01058-4
  • NAID: 40022329655
  • Peer Reviewed
• [Journal Article] Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial) (2020)
  • Author(s): Kawazoe Akihito、Kuboki Yasutoshi、Shinozaki Eiji、Hara Hiroki、Nishina Tomohiro、Komatsu Yoshito、Yuki Satoshi、Wakabayashi Masashi、Nomura Shogo、Sato Akihiro、Kuwata Takeshi、Kawazu Masahito、Mano Hiroyuki、Togashi Yosuke、Nishikawa Hiroyoshi、Yoshino Takayuki
  • Journal Title: Clinical Cancer Research Volume: 26 Issue: 22 Pages: 5887-5894
  • DOI: 10.1158/1078-0432.ccr-20-1803
  • Peer Reviewed / Open Access
• [Journal Article] An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells (2020)
  • Author(s): Shogo Kumagai, Yosuke Togashi, Chika Sakai, Akihito Kawazoe, Masahito Kawazu, Toshihide Ueno, Eiichi Sato, Takeshi Kuwata, Takahiro Kinoshita, Masami Yamamoto, Sachiyo Nomura, Tetsuya Tsukamoto, Hiroyuki Mano, Kohei Shitara, Hiroyoshi Nishikawa
  • Journal Title: Immunity Volume: 14 Issue: 1 Pages: 187-203
  • DOI: 10.1016/j.immuni.2020.06.016
  • NAID: 120006952281
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Association between the mutational smoking signature and the immune microenvironment in lung adenocarcinoma (2020)
  • Author(s): Sato Kei、Mimaki Sachiyo、Yamashita Riu、Togashi Yosuke、Naito Tomoyuki、Udagawa Hibiki、Katsumata Shinya、Nakasone Shoko、Miyoshi Tomohiro、Tane Kenta、Aokage Keiju、Sugano Masato、Kojima Motohiro、Fujii Satoshi、Kuwata Takeshi、Ochiai Atsushi、Goto Koichi、Tsuboi Masahiro、Tsuchihara Katsuya、Ishii Genichiro
  • Journal Title: Lung Cancer Volume: 147 Pages: 12-20
  • DOI: 10.1016/j.lungcan.2020.06.029
  • Peer Reviewed
• [Journal Article] Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603) (2020)
  • Author(s): Fukuoka Shota、Hara Hiroki、Takahashi Naoki、Kojima Takashi、Kawazoe Akihito、Asayama Masako、Yoshii Takako、Kotani Daisuke、Tamura Hitomi、Mikamoto Yuichi、Hirano Nami、Wakabayashi Masashi、Nomura Shogo、Sato Akihiro、Kuwata Takeshi、Togashi Yosuke、Nishikawa Hiroyoshi、Shitara Kohei
  • Journal Title: Journal of Clinical Oncology Volume: 38 Issue: 18 Pages: 2053-2061
  • DOI: 10.1200/jco.19.03296
  • Peer Reviewed
• [Journal Article] TENERGY: Multicenter Phase II Study of Atezolizumab Monotherapy Following Definitive Chemoradiotherapy With 5-FU Plus Cisplatin in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma (2020)
  • Author(s): Bando H, Kotani D, Tsushima T, Hara H, Kadowaki S, Kato K, Chin K, Yamaguchi K, Kageyama SI, Hojo H, Nakamura M, Tachibana H, Wakabayashi M, Fukutani M, Togashi Y, Fuse N, Nishikawa H, Kojima T.
  • Journal Title: BMC Cancer Volume: 20 Issue: 1 Pages: 336-336
  • DOI: 10.1186/s12885-020-06716-5
  • Peer Reviewed / Open Access
• [Journal Article] The potential application of PD-1 blockade therapy for early-stage biliary tract cancer. (2020)
  • Author(s): Umemoto K, Togashi Y, Arai Y, Nakamura H, Takahashi S, Tanegashima T, Kato M, Nishikawa T, Sugiyama D, Kojima M, Gotohda N, Kuwata T, Ikeda M, Shibata T, Nishikawa H.
  • Journal Title: Int Immunol. Volume: 32 Issue: 4 Pages: 273-281
  • DOI: 10.1093/intimm/dxz080
  • Peer Reviewed / Open Access
• [Presentation] Next cancer immunotherapy beyond PD-1 blockade (2023)
  • Author(s): Yosuke Togashi
  • Organizer: 第20回日本臨床腫瘍学会学術集会
  • Invited
• [Presentation] プレシジョンがん免疫療法の開発に向けた研究 (2022)
  • Author(s): 猪爪 隆史, 川島 秀介, 松澤 高光, 松江 弘之, 田渕 亜希子, 大沼 毅紘, 川村 龍吉, 島田 眞路, 冨樫 庸介
  • Organizer: 日本研究皮膚科学会第47回年次学術大会・総会
• [Presentation] 中型先天性色素性母斑とそこから生じた悪性黒色腫における遺伝子変異状況の比較 (2022)
  • Author(s): 保延 亜希子, 大沼 毅紘, 出口 順啓, 島田 眞路, 川村 龍吉, 坂井 和子, 西尾 和人, 冨樫 庸介, 猪爪 隆史
  • Organizer: 日本研究皮膚科学会第47回年次学術大会・総会
• [Presentation] その機能がnon-inflamedな腫瘍微小環境を誘導し得る逆説的なネオ抗原の存在(Paradoxical neoantigens; neoantigens can paradoxically induce a non-inflamed tumor microenvironment via gene functions.) (2022)
  • Author(s): 石野 貴雅, 上野 敏秀, 上田 優輝, 間野 博行, 石原 聡一郎, 加藤 直也, 河津 正人, 冨樫 庸介
  • Organizer: 第81回日本癌学会学術総会
• [Presentation] 腫瘍微小環境の1細胞解析(Single-cell analyses for the tumor microenvironment) (2022)
  • Author(s): 冨樫 庸介
  • Organizer: 第81回日本癌学会学術総会
  • Invited
• [Presentation] 腫瘍微小環境における制御性T細胞に特徴的な代謝学的チェックポイントの同定(Identification of a distinctive metabolic checkpoint of regulatory T cells in the tumor microenvironment) (2022)
  • Author(s): 熊谷 尚悟, 小山 正平, 板橋 耕太, 冨樫 庸介, 吉田 達哉, 石井 源一郎, 河津 正人, 山崎 直也, 坪井 正博, 谷田部 恭, 木下 敬弘, 土井 俊彦, 設楽 絋平, 間野 博行, 西川 博嘉
  • Organizer: 第81回日本癌学会学術総会
  • Invited
• [Presentation] B細胞性リンパ腫におけるPD-L2の生物学的機能と調節機序の解析(Dissecting biological function and regulation of PD-L2 in B-cell lymphoma) (2022)
  • Author(s): 新垣 清登, 古屋 淳史, 湯淺 光博, 斎藤 優樹, 田畑 真梨子, Marni McClure, 片山 琴絵, 冨樫 庸介, 井元 清哉, 木暮 泰寛, 片岡 圭亮
  • Organizer: 第63回日本リンパ網内系学会学術集会・総会
• [Presentation] がん免疫療法のバイオマーカー (2022)
  • Author(s): 冨樫 庸介
  • Organizer: 第63回日本臨床細胞学会総会
  • Invited
• [Presentation] 消化器癌における免疫治療と分子標的治療の基礎研究と臨床 腫瘍微小環境から考えるがん免疫療法 (2022)
  • Author(s): 冨樫 庸介
  • Organizer: 第108回日本消化器病学会総会
  • Invited
• [Presentation] Neoantigen paradox; neoantigens do not always induce an inflamed tumor microenvironment. (2022)
  • Author(s): Takamasa Ishino, Shunsuke Kawashima, Etsuko Tanji, Sadahisa Ogasawara, Naoya Kato, Masahito Kawazu, Yosuke Togashi.
  • Organizer: 12TH AACR-JCA JOINT CONFERENCE
  • Int'l Joint Research
• [Presentation] Clonal evolution in a tumor microenvironment (2022)
  • Author(s): Yosuke Togashi
  • Organizer: 12TH AACR-JCA JOINT CONFERENCE
  • Int'l Joint Research / Invited
• [Presentation] 次世代がん免疫療法を目指して (2022)
  • Author(s): 冨樫 庸介
  • Organizer: 第60回日本癌治療学会学術集会
  • Invited
• [Presentation] Mitochondrial abnormality in the tumor microenvironment and antitumor immunity (2022)
  • Author(s): 冨樫 庸介
  • Organizer: 第45回分子生物学会年会
• [Presentation] 腫瘍微小環境のクローン進展 (2022)
  • Author(s): 長﨑譲慈、冨樫庸介
  • Organizer: 第35回バイオセラピー学会
  • Invited
• [Presentation] 腫瘍微小環境から考えるがん免疫療法のバイオマーカー (2022)
  • Author(s): 冨樫 庸介
  • Organizer: 第63回日本肺癌学会学術集会
  • Invited
• [Presentation] Tumor-infiltrating PD-1+ effector T cells and reguratory T cells as novel biomarkers and therapeutic targets for cancer immunotherapies. (2022)
  • Author(s): Yosuke Togashi
  • Organizer: 第51回日本免疫学会学術集会
  • Invited
• [Presentation] TIGIT blockade therapies: can they overcome resistance to PD-1 blockade therapies? (2022)
  • Author(s): Yosuke Togashi
  • Organizer: 第26回国際がん化学療法シンポジウム
  • Invited
• [Presentation] Clonal evolution in the tumor microenvironment (2022)
  • Author(s): Yosuke Togashi
  • Organizer: HCA Asia
  • Int'l Joint Research / Invited
• [Presentation] Single-cell sequencing for a tumor microenvironment (2022)
  • Author(s): Yosuke Togashi
  • Organizer: 第19回日本臨床腫瘍学会学術集会
  • Invited
• [Presentation] CD155/TIGIT axisは免疫チェックポイント阻害剤のinflamed resistanceに関与する (2021)
  • Author(s): 猪爪 隆史, 川島 秀介, 河津 正人, 池原 譲, 木庭 幸子, 中村 泰大, 梅田 善康, 川崎 朋範, 川村 龍吉, 大沼 毅紘, 保延 亜希子, 冨樫 庸介
  • Organizer: 日本がん免疫学会総会
• [Presentation] 腫瘍局所における代謝機構を介した制御性T細胞の新規PD-1発現機構の解明 (2021)
  • Author(s): 熊谷 尚悟, 鎌田 貴裕, 冨樫 庸介, 小山 正平, 川添 彬人, 河津 正人, 青景 圭樹, 名嘉眞 健太, 吉田 達哉, 山崎 直也, 大江 裕一郎, 坪井 正博, 設樂 紘平, 間野 博行, 西川 博嘉
  • Organizer: 日本がん免疫学会総会
• [Presentation] 中型先天性色素性母斑とそこから生じた悪性黒色腫と転移巣における遺伝子変異状況の比較 (2021)
  • Author(s): 田渕 亜希子, 大沼 毅紘, 出口 順啓, 島田 眞路, 川村 龍吉, 坂井 和子, 西尾 和人, 冨樫 庸介, 猪爪 隆史
  • Organizer: 日本皮膚科学会総会
• [Presentation] 免疫チェックポイント阻害剤の耐性メカニズムを考える (2021)
  • Author(s): 冨樫庸介
  • Organizer: 第37回日本皮膚悪性腫瘍学会学術大会
  • Invited
• [Presentation] がん免疫とは何か：解析手法の基礎 (2021)
  • Author(s): 冨樫庸介
  • Organizer: 第80回日本癌学会学術総会
  • Invited
• [Presentation] Precision Medicine of Cancer Immunotherapy (2021)
  • Author(s): Yosuke Togashi
  • Organizer: 第80回日本癌学会学術総会
  • Invited
• [Presentation] 胸部腫瘍（非小細胞肺癌を除く）に対する複合免疫療法を考える (2021)
  • Author(s): 冨樫庸介
  • Organizer: 第62回日本肺癌学会学術集会
  • Invited
• [Presentation] Several types of “exhausted” T cells in the tumor microenvironment (2021)
  • Author(s): Yosuke Togashi
  • Organizer: 第50回日本免疫学会総会
  • Invited
• [Presentation] Cancer immunogenomics for the next stage of precision medicine (2021)
  • Author(s): Yosuke Togashi
  • Organizer: 第25回国際がん化学療法シンポジウム
  • Invited
• [Presentation] 腫瘍微小環境におけるクローン進展 (2021)
  • Author(s): 冨樫庸介
  • Organizer: 第34回バイオセラピー学会
  • Invited
• [Presentation] The Future of Immunotherapy (2021)
  • Author(s): Yosuke Togashi
  • Organizer: 2021 Targeted Therapy of Lung Cancer Meeting
  • Int'l Joint Research / Invited
• [Presentation] Clonal evolution in the tumor microenvironment (2021)
  • Author(s): Yosuke Togashi
  • Organizer: 第18回日本臨床腫瘍学会学術集会
  • Invited
• [Presentation] Phase II Trial of Site-Specific Treatment Based on Gene Expression and Mutation Profiling by next generation sequencing (NGS) for Patients (pts) With Cancer of Unknown Primary Site (CUP) (2021)
  • Author(s): Makoto Arai, Hidetoshi Hayashi, Hironobu Minami, Yuichi Takiguchi, Satomi Watanabe, Masanori Toyoda, Kohei Akiyoshi, Yoshihiko Segawa, Hiroki Ueda, Yasuo Iwamoto, Jun Masuda, Hirohumi Mukai, Toshio Kubo, Yosuke Togashi, Kazuko Sakai, Yoshihiko Fujita, Shuta Tomida, Yasutaka Chiba, Kazuto Nishio, and Kazuhiko Nakagawa
  • Organizer: 第18回日本臨床腫瘍学会学術集会
• [Presentation] The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma (2021)
  • Author(s): Joji Nagasaki1, Yosuke Togashi, Takeaki Sugawara, Makiko Itami, Nobuhiko Yamauchi, Junichiro Yuda, Sugano Masato, Ohara Yuuki, Yosuke Minami, Hirohisa Nakamae, Masayuki Hino, Masahiro Takeuchi, Hiroyoshi Nishikawa.
  • Organizer: 第18回日本臨床腫瘍学会学術集会
• [Presentation] Heterogeneity in congenital melanocytic nevi contributes to muliticentric melanomagenesis. (2021)
  • Author(s): Takashi Inozume, Akiko Honobe, Kazuko Sakai, Yosuke Togashi, Takehiro Ohnura, Tatsuyoshi Kawamura, Kazuto Nishio
  • Organizer: 第18回日本臨床腫瘍学会学術集会
• [Presentation] Efficacy Predictors of Preoperative CRT and Consolidation Nivolumab in Patients with Locally Advanced Rectal Cancer. (2021)
  • Author(s): Koji Inamori, Yosuke Togashi, Hideaki Bando, Yuichiro Tsukada, Shota Fukuoka,Yutaka Suzuki, Daisuke Kotani, Motohiro Kojima, Makoto Fukui, Satoshi Yuki, Yoshito Komatsu, Shigenori Homma, Akinobu Taketomi, Mamoru Uemura, Takeshi Kato, Masaaki Ito, Hiroyoshi Nishikawa, Takayuki Yoshino.
  • Organizer: 第18回日本臨床腫瘍学会学術集会
• [Presentation] TIGIT/CD155 axis mediates resistance to immunotherapies in inflamed tumors. (2021)
  • Author(s): Shusuke Kawashima, Takashi Inozume, Masahito Kawazu, Etsuko Tanji, Akiko Honobe, Takehiro Ohnuma, Tatsuyoshi Kawamura, Hiroyuki Matsue, Yosuke Togashi.
  • Organizer: 第18回日本臨床腫瘍学会学術集会
• [Presentation] Emerging biomarker for immunotherapy in head and neck cancer (2021)
  • Author(s): Yosuke Togashi
  • Organizer: 第18回日本臨床腫瘍学会学術集会
  • Invited
• [Presentation] Translational Research of VOLTAGE-A: Efficacy Predictors of Preoperative Chemoradiotherapy and Consolidation Nivolumab in Patients with both Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer (2021)
  • Author(s): Koji Inamori, Yosuke Togashi, Hideaki Bando, Yuichiro Tsukada, Shota Fukuoka, Ayako Suzuki, Yutaka Suzuki, Daisuke Kotani, Motohiro Kojima, Makoto Fukui, Satoshi Yuki, Yoshito Komatsu, Shigenori Homma, Akinobu Taketomi, Mamoru Uemura, Takeshi Kato, Masaaki Ito, Hiroyoshi Nishikawa, Takayuki Yoshino.
  • Organizer: ASCO-GI2021
• [Presentation] 腫瘍に発現するPD-L2の免疫抑制機能について (2020)
  • Author(s): 種子島 時祥, 冨樫 庸介, 東 公一, 入江 拓磨, 木下 史生, 柏木 英志, 武内 在雄, 立神 勝則, 江藤 正俊, 西川 博嘉
  • Organizer: 第108回日本泌尿器科学総会
• [Presentation] PD-L2による、自発的・治療関連抗腫瘍免疫に対する免疫抑制機能 (2020)
  • Author(s): 種子島 時祥, 冨樫 庸介, 江藤 正俊, 西川 博嘉
  • Organizer: 第72回西日本泌尿器科学総会
• [Presentation] 免疫チェックポイント阻害剤と制御性T細胞 (2020)
  • Author(s): 冨樫庸介
  • Organizer: 第24回日本がん分子標的治療学会
  • Invited
• [Presentation] Translational Research using Clinical Samples in Cancer Immunology (2020)
  • Author(s): Yosuke Togashi
  • Organizer: 第79回日本癌学会学術総会
  • Invited
• [Presentation] 免疫チェックポイント阻害剤を含む併用療法におけるバイオマーカー (2020)
  • Author(s): 冨樫庸介
  • Organizer: 第60回日本呼吸器学会学術講演会
  • Invited
• [Presentation] Cancer immunogenomics (2020)
  • Author(s): Yosuke Togashi
  • Organizer: KSMO and JSMO Joint Symposium
  • Int'l Joint Research / Invited
• [Presentation] Translational Research for Future Immunotherapy (2020)
  • Author(s): 冨樫庸介
  • Organizer: 第92回日本胃癌学会総会
  • Invited
• [Presentation] Translational research of voltage-A1: Efficacy predictors of preoperative chemoradiotherapy and subsequent nivolumab monotherapy in patients with microsatellite-stable locally advanced rectal cancer. (2020)
  • Author(s): Koji Inamori, Yosuke Togashi, Hideaki Bando, Yuichiro Tsukada, Shota Fukuoka, Ayako Suzuki, Yutaka Suzuki, Daisuke Kotani, Motohiro Kojima, Makoto Fukui, Satoshi Yuki, Yoshito Komatsu, Shigenori Homma, Akinobu Taketomi, Mamoru Uemura, Takeshi Kato, Masaaki Ito, Hiroyoshi Nishikawa, Takayuki Yoshino
  • Organizer: ASCO2020
  • Int'l Joint Research
• [Presentation] Short-Term Results of VOLTAGE-A: Nivolumab Monotherapy and Subsequent Radical Surgery Following Preoperative Chemoradiotherapy in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer. (2020)
  • Author(s): Satoshi Yuki, Hideaki Bando, Yuichiro Tsukada, Koji Inamori, Yoshito Komatsu, Shigenori Homma, Mamoru Uemura, Takeshi Kato, Daisuke Kotani, Shota Fukuoka, Naoki Nakamura, Makoto Fukui, Masashi Wakabayashi, Motohiro Kojima, Yosuke Togashi, Akihiro Sato, Hiroyoshi Nishikawa, Masaaki Ito, Takayuki Yoshino
  • Organizer: ASCO2020
  • Int'l Joint Research
• [Book] 「特集」免疫チェックポイント : 阻害薬の"耐性"に挑む : がん免疫サイクルから見出す戦略 (2022)
  • Author(s): 冨樫 庸介
  • Total Pages: 127
  • Publisher: 羊土社
• [Book] がん免疫ペディア (2022)
  • Author(s): 川瀬勝隆、冨樫庸介
  • Total Pages: 2
  • Publisher: 羊土社
• [Patent(Industrial Property Rights)] 所属リンパ節由来リンパ球を用いた細胞療法 (2022)
  • Inventor(s): 冨樫庸介、河津正人
  • Industrial Property Rights Holder: 冨樫庸介、河津正人
  • Industrial Property Rights Type: 特許
  • Filing Date: 2022